Zimmer Biomet is a global leader in musculoskeletal healthcare, specializing in joint replacement implants (knees, hips, shoulders) " a market directly tied to aging demographics. The company is well-positioned as global populations age and demand for orthopedic procedures grows steadily.
The bull case is compelling: ZBH trades at a remarkably low P/E of 8.96 with strong EPS of $10.77, suggesting significant undervaluation relative to its defensive healthcare positioning. The stock sits well below its 52-week high of $114.44, offering potential upside. Recent momentum is positive, with a 7.26% gain over 30 days and price above the 50-day moving average.
However, the bear case is notable. The stock has lost 37.58% over five years, reflecting persistent concerns around execution challenges, competitive pressure from Stryker and Smith+Nephew, and integration issues from the 2015 Biomet merger. Debt levels remain elevated, and surgical volume recovery post-COVID has been uneven.
For aging population investors, Zimmer Biomet offers strong demographic tailwinds and an attractive valuation, but operational improvement must materialize to unlock value. The current discount may represent opportunity for patient investors.